background
grow
concern
rais
regard
pandem
potenti
highli
pathogen
avian
influenza
hpai
virus
consequ
urgent
need
develop
effect
safe
vaccin
diverg
influenza
virus
present
studi
design
tetrabranch
multipl
antigen
peptid
map
base
vaccin
design
contain
sequenc
overlap
highli
conserv
extracellular
domain
matrix
protein
hpai
viru
investig
immun
respons
crossprotect
differ
clade
virus
result
result
show
vaccin
induc
strong
igg
antibodi
respons
follow
immun
mice
presenc
freund
aluminium
alum
adjuv
vaccin
limit
viral
replic
attenu
histopatholog
damag
challeng
mous
lung
vaccin
protect
immun
mice
viru
challeng
abl
counteract
weight
lost
elev
surviv
rate
follow
lethal
challeng
virus
conclus
result
suggest
present
viru
great
potenti
develop
effect
subunit
vaccin
prevent
infect
broad
spectrum
hpai
virus
reemerg
highli
pathogen
avian
influenza
hpai
caus
fatal
case
among
total
infect
individu
therefor
urgent
need
develop
safe
effect
antivir
strategi
prevent
futur
pandem
hpai
among
vaccin
still
effect
mean
prevent
influenza
viru
infect
due
current
vaccin
technolog
face
annual
problem
vaccinestrain
match
conserv
antigen
influenza
viru
becom
promis
target
develop
influenza
vaccin
broad
crossprotect
comparison
surfac
protein
virus
matrix
protein
conserv
nativ
protein
exist
homotetram
form
two
disulfid
link
dimer
monom
consist
amino
acid
extracellular
domain
protein
remark
conserv
across
influenza
subtyp
passiv
transfer
monoclon
antibodi
mab
acceler
lung
viral
clearanc
mab
recogn
nterminu
highli
conserv
epitop
protect
mice
lethal
influenza
viru
challeng
impli
particular
may
serv
attract
vaccin
target
current
rapid
evolut
viru
cocircul
multipl
antigen
variant
multipl
region
determin
develop
vaccin
crossprotect
diverg
virus
would
inevit
although
number
vaccin
report
provid
broadspectrum
protect
ordinari
human
influenza
viru
infect
crossprotect
effect
diverg
virus
undocu
present
studi
design
synthes
tetrabranch
multipl
antigen
peptid
map
deriv
sequenc
viru
strain
denot
aim
develop
vaccin
induct
immun
respons
crossprotect
vaccin
anim
lethal
challeng
diverg
viru
strain
evalu
humor
immun
respons
potenti
induc
mice
vaccin
plu
freund
aluminium
alum
adjuv
describ
method
igg
antibodi
detect
mous
serum
sampl
elisa
shown
figur
induc
strong
igg
antibodi
respons
highest
titer
reach
respect
day
post
last
boost
vaccin
contrast
background
level
antibodi
respons
detect
mice
receiv
adjuv
alon
two
phylogenet
distinguish
viru
isol
select
evalu
protect
immun
afford
vaccin
vivo
two
week
last
boost
mice
challeng
ld
viru
vn
five
day
postchalleng
lung
remov
infect
mice
infecti
viru
titer
lung
tissu
measur
determin
protect
effect
vaccin
viral
clearanc
compar
adjuv
control
fca
fia
alum
viru
titer
lung
vaccin
mice
significantli
lower
viru
challeng
p
figur
suggest
vaccin
induc
protect
immun
viral
replic
vaccin
mice
examin
lung
tissu
viruschalleng
mice
reveal
dramat
histopatholog
damag
pulmonari
airway
parenchym
tissu
adjuv
group
includ
sever
damag
bronchial
epithelium
necrosi
desquam
pulmonari
vascular
dilat
congest
infiltr
promin
number
lymphocyt
accompani
exud
sever
edema
especi
around
vessel
well
broaden
interstiti
space
fuse
alveoli
wall
focal
hemorrhag
figur
contrast
lung
mice
exhibit
less
figur
antibodi
respons
induc
vaccin
mice
vaccin
plu
fcafia
sc
alum
adjuv
total
time
mice
receiv
fcafia
alum
alon
serv
adjuv
control
mous
sera
collect
preimmun
day
posteach
immun
detect
antibodi
elisa
endpoint
titer
sampl
determin
highest
dilut
yield
od
nm
valu
greater
twice
similarli
dilut
serum
sampl
collect
prevaccin
data
express
geometr
mean
titer
gmt
standard
deviat
sd
mice
per
group
lower
limit
detect
indic
dot
line
experi
repeat
three
time
histopatholog
chang
accompani
mild
pulmonari
interstiti
pneumonia
moder
lymphocyt
infiltr
figur
data
impli
vaccin
may
protect
mice
lethal
challeng
diverg
virus
combin
limit
viral
replic
lung
attenu
virusinduc
lung
patholog
receiv
lethal
dose
ld
two
viru
strain
vaccin
mice
evalu
term
crossprotect
abil
daili
observ
clinic
symptom
includ
weight
loss
surviv
rate
two
week
histopatholog
examin
follow
remov
lung
tissu
day
day
viru
infect
adjuv
control
mice
fcafia
alum
develop
obviou
clinic
sign
includ
ruffl
fur
hunch
postur
rapid
breath
inact
paralysi
posterior
limb
clinic
sign
either
observ
delay
day
vaccin
group
vaccin
mice
clinic
sign
exhibit
slight
partial
piloerect
day
recov
moreov
compar
adjuv
control
vaccin
mice
surviv
challeng
observ
delay
onset
ill
longer
surviv
day
observ
protect
clinic
sign
correl
chang
bodi
weight
adjuv
group
bodi
weight
dramat
decreas
even
reach
near
sever
weight
loss
viru
infect
contrast
averag
bodi
weight
vaccin
group
slightli
decreas
less
day
challeng
steadili
increas
figur
control
mice
receiv
fcafia
alum
adjuv
alon
die
viru
challeng
mice
vaccin
surviv
lethal
viru
challeng
figur
significantli
increas
surviv
rate
p
day
postchalleng
lung
tissu
surviv
mice
remov
evalu
viral
replic
histopatholog
damag
viru
detect
lung
surviv
mice
lung
tissu
mice
present
almost
normal
structur
data
shown
data
confirm
vaccin
afford
crossprotect
lethal
challeng
diverg
virus
crossprotect
vaccin
antigen
variant
viru
import
compon
prophylact
strategi
possibl
human
pandem
lung
collect
detect
viru
titer
five
day
later
data
express
log
tcid
g
lung
tissu
lower
limit
detect
log
tcid
g
tissu
indic
dot
line
data
present
gmt
sd
mice
per
group
indic
p
compar
fcafia
control
group
mean
p
compar
alum
control
group
experi
repeat
three
time
although
highli
conserv
influenza
viru
one
promis
target
develop
univers
influenza
vaccin
strategi
would
requir
improv
immunogen
vaccin
base
contain
amino
acid
high
molar
ratio
dens
pack
multipl
copi
target
antigen
map
system
shown
stimul
better
immun
respons
singlechain
peptid
mozdzanowska
et
al
report
map
system
present
human
influenza
sequenc
effect
immunogen
igg
antibodi
mice
immun
bind
specif
cell
howev
unclear
whether
could
use
vaccin
candid
provid
effect
protect
hpai
viru
differ
human
influenza
virus
virus
circul
domest
wild
bird
far
virus
lead
human
infect
still
belong
avian
type
vaccin
design
sequenc
human
influenza
viru
subtyp
may
provid
protect
viru
lead
human
infect
moreov
amino
acid
region
consist
host
restrict
specif
studi
design
tetrabranch
form
contain
copi
sequenc
overlap
hpai
strain
figur
high
titer
antibodi
respons
could
induc
follow
immun
plu
freund
adjuv
commonli
use
adjuv
anim
experi
alum
common
adjuv
human
vaccin
figur
although
shown
igg
antibodi
exhibit
abil
directli
neutral
viru
vitro
antivir
effect
vaccin
mediat
antibodi
antigen
mechan
antibodi
mediat
antivir
effect
could
due
antibodydepend
cellmedi
cytotox
adcc
andor
complementmedi
cytotox
cdc
therefor
induct
antibodi
respons
necessari
vaccin
prevent
viru
infect
strikingli
vaccin
freund
alum
adjuv
confer
crossprotect
lethal
challeng
homolog
strain
also
diverg
strain
vaccin
mice
delay
onset
ill
prolong
surviv
allevi
bodi
weight
loss
limit
viral
replic
restrict
histopatholog
damag
lung
tissu
figur
figur
figur
clade
categor
strain
base
phylogenet
analysi
ha
gene
virus
seem
preval
china
sinc
late
also
respons
human
infect
lao
malaysia
vietnam
includ
one
recent
human
isol
china
compar
monomer
peptidebas
vaccin
vaccin
could
induc
stronger
protect
immun
due
immun
enhanc
effect
thelper
epitop
vaccin
term
safeti
synthet
peptidebas
vaccin
superior
dna
adenovir
vector
recombin
proteinbas
vaccin
exampl
dna
vaccin
potenti
integr
viral
genom
human
dna
develop
autoimmun
induc
antibiot
resist
recombin
proteinbas
vaccin
may
contamin
endotoxin
unwant
antigen
cell
cultur
spite
rel
higher
cost
product
synthet
peptidebas
vaccin
rapidli
design
synthes
conveni
storag
transport
make
vaccin
better
choic
speed
develop
effect
safe
vaccin
combat
emerg
influenza
pandem
base
evid
find
approach
develop
vaccin
broad
crossprotect
feasibl
strategi
incorpor
appropri
adjuv
present
map
system
modif
present
consensu
sequenc
virus
vaccin
target
andor
select
express
form
might
help
achiev
full
crossprotect
lethal
viru
infect
effect
approach
need
determin
studi
data
report
support
concept
develop
vaccin
candid
could
provid
crossprotect
diverg
hpai
virus
vaccin
base
highli
conserv
target
antigen
virus
might
use
combin
current
influenza
vaccin
enhanc
protect
prevent
possibl
futur
human
pandem
influenza
present
studi
synthes
tetrabranch
base
sequenc
viru
vaccin
induc
strong
igg
antibodi
respons
abl
protect
mice
lethal
challeng
virus
base
evid
find
approach
develop
vaccin
broad
crossprotect
feasibl
data
report
support
concept
figur
show
composit
sequenc
femal
balbc
mice
week
purchas
laboratori
anim
unit
hous
anim
facil
univers
hong
kong
follow
approv
anim
care
protocol
mice
rest
week
immun
anim
studi
approv
depart
health
govern
hong
kong
special
administr
region
univers
anim
ethic
committe
univers
hong
kong
hpai
viru
isol
use
studi
virus
grown
allanto
caviti
embryon
chicken
egg
viruscontain
allanto
fluid
harvest
store
aliquot
use
ld
viru
stain
determin
mice
serial
dilut
viru
stock
infecti
experi
relat
virus
perform
approv
biosafeti
level
facil
univers
hong
kong
mice
subcutan
sc
prime
vaccin
plu
freund
complet
adjuv
fca
sigma
boost
twice
amount
immunogen
plu
freund
incomplet
adjuv
fia
sigma
interv
parallel
experi
mice
also
intramuscularli
im
vaccin
amount
immunogen
plu
alum
adjuv
sigma
condit
mice
inject
freund
alum
adjuv
use
respect
control
mous
sera
collect
immun
day
posteach
vaccin
detect
antibodi
respons
two
week
postlast
vaccin
mice
intraperiton
ip
anesthet
ketaminexylazin
mgkg
intranas
challeng
viru
stain
infect
mice
observ
weigh
daili
week
lung
tissu
collect
euthan
mice
day
postchalleng
virolog
test
histopatholog
analysi
igg
antibodi
vaccin
mous
sera
detect
elisa
previous
describ
modif
briefli
microtit
plate
precoat
overnight
block
bsa
contain
pb
serial
dilut
mous
sera
ad
plate
follow
ad
hrpconjug
rabbit
antimous
igg
invitrogen
carlsbad
ca
h
assay
develop
use
tmb
zyme
carlsbad
ca
reaction
stop
ad
h
absorb
nm
measur
elisa
plate
reader
micropl
reader
tecan
nc
lung
tissu
euthan
mice
asept
remov
homogen
minim
essenti
medium
mem
plu
antibiot
achiev
wv
suspens
lung
tenfold
serial
dilut
sampl
ad
quadrupl
monolay
madindarbi
canin
kidney
mdck
cell
seed
cell
cultur
plate
h
infect
allow
absorb
h
fresh
medium
ad
cell
continu
incub
h
viru
cytopath
effect
cpe
observ
daili
viral
titer
determin
hemagglutinin
ha
test
indic
follow
fifti
microlitr
turkey
red
blood
cell
lampir
biolog
laboratori
pipersvil
pa
ad
cell
cultur
supernat
incub
room
temperatur
min
well
contain
ha
score
posit
viru
titer
calcul
reed
muench
method
express
log
tcid
g
lung
tissu
lung
tissu
challeng
mice
immedi
fix
neutral
buffer
formalin
embed
paraffin
wax
section
made
thick
mount
slide
histopatholog
chang
examin
h
e
stain
observ
light
microscopi
previous
describ
signific
surviv
curv
analyz
kaplanmei
surviv
analysi
logrank
test
data
analyz
use
student
test
p
consid
signific
analys
perform
graphpad
prism
softwar
